Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AbbVie Inc.
ABBV
$223.93
Name : AbbVie Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $395,770,429,440.00
EPSttm : 1.32
finviz dynamic chart for ABBV
AbbVie Inc.
$223.93
1.70%
$3.75

Float Short %

1.02

Margin Of Safety %

2

Put/Call OI Ratio

0.86

EPS Next Q Diff

1.25

EPS Last/This Y

8.24

EPS This/Next Y

3.61

Price

224.02

Target Price

250.54

Analyst Recom

1.74

Performance Q

-2.72

Relative Volume

1.62

Beta

0.34

Ticker: ABBV




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-08ABBV223.620.790.78297942
2025-12-09ABBV222.990.800.30303081
2025-12-10ABBV225.170.780.24307834
2025-12-11ABBV223.80.780.76309817
2025-12-12ABBV223.330.780.40312187
2025-12-15ABBV227.460.780.41309281
2025-12-16ABBV223.610.770.62312224
2025-12-17ABBV224.320.780.49317638
2025-12-18ABBV222.870.770.99319160
2025-12-19ABBV226.840.780.51322069
2025-12-22ABBV227.910.840.42261292
2025-12-23ABBV228.740.830.77266952
2025-12-26ABBV230.080.830.98272737
2025-12-29ABBV230.850.840.50266718
2025-12-30ABBV229.710.830.62270299
2025-12-31ABBV228.490.830.90273062
2026-01-02ABBV229.320.840.53275318
2026-01-05ABBV220.190.850.62271705
2026-01-06ABBV2240.860.75281224
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-08ABBV223.1255.2- 10.64
2025-12-09ABBV222.9955.226969.310.64
2025-12-10ABBV222.9955.227255.810.64
2025-12-11ABBV223.9855.226830.510.64
2025-12-12ABBV223.3255.326905.110.64
2025-12-15ABBV227.4555.327487.910.64
2025-12-16ABBV227.4555.226523.810.64
2025-12-17ABBV224.3455.227066.510.64
2025-12-18ABBV222.9855.226824.010.64
2025-12-19ABBV226.7855.227468.110.64
2025-12-22ABBV227.5855.227076.510.64
2025-12-23ABBV228.8255.227068.810.64
2025-12-26ABBV229.9855.226995.810.64
2025-12-29ABBV230.9655.227101.510.64
2025-12-30ABBV229.7255.226852.710.64
2025-12-31ABBV228.4955.226836.710.64
2026-01-02ABBV229.2855.227079.310.64
2026-01-05ABBV220.2055.225900.810.64
2026-01-06ABBV224.0255.227458.310.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-08ABBV-3.380.151.06
2025-12-09ABBV-3.380.151.06
2025-12-10ABBV-3.380.151.03
2025-12-11ABBV-3.380.151.03
2025-12-12ABBV-3.380.151.03
2025-12-15ABBV-3.380.151.03
2025-12-16ABBV-3.380.151.03
2025-12-17ABBV-3.380.151.03
2025-12-18ABBV-3.380.151.03
2025-12-19ABBV-3.380.151.03
2025-12-22ABBV-3.380.091.03
2025-12-23ABBV-3.380.091.03
2025-12-26ABBV-3.380.091.02
2025-12-29ABBV-3.380.091.02
2025-12-30ABBV-3.380.091.02
2025-12-31ABBV-3.380.091.02
2026-01-02ABBV-3.380.091.02
2026-01-05ABBV-3.380.121.02
2026-01-06ABBV-3.380.121.02
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

1.86

Avg. EPS Est. Current Quarter

3.35

Avg. EPS Est. Next Quarter

3.11

Insider Transactions

-3.38

Institutional Transactions

0.12

Beta

0.34

Average Sales Estimate Current Quarter

16391

Average Sales Estimate Next Quarter

14737

Fair Value

229.39

Quality Score

60

Growth Score

80

Sentiment Score

14

Actual DrawDown %

8.5

Max Drawdown 5-Year %

-21.9

Target Price

250.54

P/E

168.97

Forward P/E

15.66

PEG

0.97

P/S

6.64

P/B

P/Free Cash Flow

20.11

EPS

1.33

Average EPS Est. Cur. Y​

10.64

EPS Next Y. (Est.)

14.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.94

Relative Volume

1.62

Return on Equity vs Sector %

-116

Return on Equity vs Industry %

-125.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

27458.3
AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 55000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading